Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...